You are here: Industry Insights > Novartis

News List

Novartis makes offer to acquire French CDMO CellforCure pharmaceutical-technology
December 24, 2018
Novartis has made an offer to acquire CellforCure, a France-based contract development and manufacturing organisation (CDMO) producing cell and gene therapies in Europe, from LFB for an undisclosed amount.....
Novartis oncology CEO quits after less than a year pharmaphorum
December 21, 2018
Novartis has appointed Susanne Schaffert to lead its oncology division after incumbent CEO Liz Barrett decided to leave for another job.
Novartis Announces New CEO of Oncology Business Unit americanpharmaceuticalreview
December 21, 2018
Novartis announced Susanne Schaffert, Ph.D., currently President, Advanced Accelerator Applications (AAA), a Novartis company, has been appointed CEO Novartis Oncology.....
Pfizer and Novartis collaborate to find liver disease therapy pharmaphorum
December 19, 2018
Pfizer has joined forces with Novartis to bring together the therapies they have been working on independently, to treat non-alcoholic steatohepatitis (NASH).....
Novartis, still struggling with Kymriah manufacturing, is providing some out-of-spec doses to patients who ask fiercepharma
December 19, 2018
Novartis released some new data on CAR-T drug Kymriah this month that it hopes will improve the uptake of the drug. But Novartis also continues to wrestle with manufacturing issues that have kept some doses from meeting specifications, a problem that is a
Novartis considers reinsurance model to fund next generation therapies pharmaceutical-technology
December 18, 2018
Novartis has announced it is looking into working with reinsurers as a way to help healthcare providers fund the ultra-high cost of new personalised therapies......
Novartis withdraw marketing application for heart drug pharmafile
December 18, 2018
Swiss multinational Novartis has withdrawn a European Medicines Agency (EMA) marketing application for canakinumab for the prevention of serious events such as stroke, myocardial infarction (MI) or death in patients who have had an MI.
Novartis pulls EU filing for canakinumab pharmatimes
December 18, 2018
Novartis has pulled back its application to market canakinumab for the prevention of serious events such as stroke, myocardial infarction (MI) or death in patients who have had an MI in Europe.
Novartis pulls EU filing for canakinumab for the prevention of major cardiovascular events firstwordpharma
December 17, 2018
The European Medicines Agency said Friday that Novartis withdrew a marketing application seeking approval of canakinumab for the prevention of serious events such as stroke, myocardial infarction (MI) or death in patients who have had an MI.
J&J says its psoriasis drug superior to Novartis treatment: Study expressbpd
December 14, 2018
Psoriasis is a chronic condition that causes an overproduction of skin cells, resulting in inflamed, red lesions or plaques, which can be itchy and painful

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page